Supplemental Online Tables
Files in this Data Supplement:
- Online Tables (PDF) -
Online Table 1: The characteristics of Gd-based contrast agents approved for MRI of the CNS
Online Table 2: Principal findings from prospective, intraindividual crossover studies of GBCAs at approved dose (0.1 mmol/kg body weight)
- Online Tables (PDF) -
Jump to section
Related Articles
Cited By...
- Injection Rates for Vessel Optimization During Magnetic Resonance Angiography
- Twofold improved tumor-to-brain contrast using a novel T1 relaxation-enhanced steady-state (T1RESS) MRI technique
- Safety and Diagnostic Efficacy of Gadobenate Dimeglumine in MRI of the Brain and Spine of Neonates and Infants
- High Signal Intensity in the Dentate Nucleus and Globus Pallidus on Unenhanced T1-Weighted MR Images: Comparison between Gadobutrol and Linear Gadolinium-Based Contrast Agents
- Deep Brain Nuclei T1 Shortening after Gadobenate Dimeglumine in Children: Influence of Radiation and Chemotherapy
- The Benefits of High Relaxivity for Brain Tumor Imaging: Results of a Multicenter Intraindividual Crossover Comparison of Gadobenate Dimeglumine with Gadoterate Meglumine (The BENEFIT Study)
- Are There Differences between Macrocyclic Gadolinium Contrast Agents for Brain Tumor Imaging? Results of a Multicenter Intraindividual Crossover Comparison of Gadobutrol with Gadoteridol (the TRUTH Study)